Skyrizi (risankizumab-rzaa)

Adult Dosing .

Dosage forms:  INJ (auto-injector): 150 mg; INJ (pre-filled syringe): 150 mg per mL; INJ (on-body injector): 180 mg, 360 mg; INJ (vial): various

Special Note

[formulation clarification]

Info: nonproprietary name = risankizumab-rzaa

psoriasis, moderate-severe plaque

[150 mg SC q12wk]

Start: 150 mg SC x1 on wk 0, 4, then q12wk

psoriatic arthritis

[150 mg SC q12wk]

Start: 150 mg SC x1 on wk 0, 4, then q12wk; Info: use alone or w/ non-biologic DMARDs

Crohn dz, moderate-severe

[induction tx]

Dose: 600 mg IV x1 on wk 0, 4, 8

[maintenance tx]

Dose: 180 mg or 360 mg SC q8wk; Start: 4wk after last induction dose; Info: use lowest effective dose

ulcerative colitis, moderate-severe

[induction tx]

Dose: 1200 mg IV x1 on wk 0, 4, 8

[maintenance tx]

Dose: 180 mg or 360 mg SC q8wk; Start: 4wk after last induction dose; Info: use lowest effective dose

renal dosing

[not defined]

renal impairment: not defined

HD/PD: not defined

hepatic dosing

[Crohn dz]

hepatic impairment: not defined; Info: consider alternative tx if cirrhosis

[all other indications]

hepatic impairment: not defined

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.